ReviewIDrugs : the investigational drugs journal2010

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

Ying Zhang et al.PubMed ↗Full text ↗

No numbers read from the abstract.